If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epithalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
p53-HDM2-binding · penetratin-fused research peptide
Supply and ordering
Ask sales about PNC-27 availability, order quantities, packaging, and batch documentation. Include other catalog items in the same inquiry if you are planning a combined or recurring order.
Overview
PNC-27 is a 32-amino-acid fusion research peptide combining the HDM-2-binding domain of p53 (residues 12-26) at the N-terminus with the penetratin cell-penetrating peptide (residues 43-58 of the Antennapedia homeodomain) at the C-terminus. The fusion produces a molecule that can cross plasma membranes via the penetratin moiety and then engage HDM-2 (the human homolog of MDM2) intracellularly. The most studied property of PNC-27 is selective induction of membrane pore formation in cells expressing high levels of HDM-2 on the cell surface, a property associated with malignant transformation in several tumor types but absent from most healthy cells. This selectivity is the basis for PNC-27's broad use in tumor-selective membrane-disruption research. PeptideXpo supplies PNC-27 as a lyophilized powder to a ≥99.0% HPLC purity specification. The 32-residue sequence with mixed hydrophobic and cationic regions is at the more demanding end of routine SPPS, and every released lot comes with its batch COA covering peak-integration HPLC purity and mass-spec identity; water content and LC-MS/MS sequence verification are available on request and listed on the COA when tested. The penetratin moiety makes PNC-27 prone to surface adsorption like LL-37, so working dilutions should be prepared in low-bind plasticware with BSA or Tween-20 carrier to suppress concentration loss at sub-μg/mL working concentrations.
Who buys this, and why
Buyers for longevity-class peptides span research labs working on telomere, collagen, and circadian-rhythm models, plus cosmetic-formulation OEMs incorporating peptides like GHK-Cu into anti-aging finished products. Copper peptides in particular require attention to chelator-free water and EDTA-free buffers in downstream formulation work, incompatibility there is the most common cause of "the peptide didn't work" support tickets in this class.
Primary buyer fit: academic and contract research laboratories.
Specifications
Also available as a nasal spray (US stock)
Besides lyophilized vials, PNC-27 is stocked in the US as a ready-to-use nasal spray.
Documentation available on request
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COAPNC-27 5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Regulatory note
Research peptide; CAS is not consistently registered across suppliers. Sold for research use only.
Selected literature
Frequently asked questions
PNC-27's N-terminal HDM-2-binding domain (derived from p53 residues 12-26) is the bioactive moiety, it engages HDM-2 protein and disrupts the HDM-2/membrane interaction in cells displaying surface HDM-2. The C-terminal penetratin domain (derived from the Antennapedia homeodomain) is the delivery vehicle, it confers cell-penetration capability that the bioactive moiety alone would not have. The fusion is the classic two-domain cell-penetrating-peptide design: a recognition or binding domain attached to a transduction domain, allowing intracellular access for a molecule that would otherwise be excluded by the plasma membrane.
The selectivity is hypothesized to derive from differential surface display of HDM-2 protein. In normal cells, HDM-2 is primarily a nuclear protein with limited plasma-membrane localization; in many tumor types, HDM-2 is aberrantly displayed on the plasma membrane, where it becomes accessible to extracellular PNC-27 binding. When PNC-27 binds plasma-membrane-displayed HDM-2 in cancer cells, the interaction is hypothesized to drive membrane pore formation and selective tumor-cell death. Normal cells lacking surface HDM-2 are less susceptible. The selectivity is the basis for PNC-27's research interest as a tumor-selective membrane-disruption tool, though the mechanism details continue to be refined in the published literature.
Yes. PNC-27 is also stocked as a ready-to-use nasal spray (5 mg) in 10 mL or 20 mL bottles, from 10 bottles of each. These orders ship from our US stock; ask our sales team for details and a quote.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
